WO2000040273A3 - Traitement de maladies virales a l'aide d'un polynucleotide exprimant l'interferon omega - Google Patents

Traitement de maladies virales a l'aide d'un polynucleotide exprimant l'interferon omega Download PDF

Info

Publication number
WO2000040273A3
WO2000040273A3 PCT/US1999/030843 US9930843W WO0040273A3 WO 2000040273 A3 WO2000040273 A3 WO 2000040273A3 US 9930843 W US9930843 W US 9930843W WO 0040273 A3 WO0040273 A3 WO 0040273A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
viral diseases
interferon omega
expressing polynucleotide
polynucleotide
Prior art date
Application number
PCT/US1999/030843
Other languages
English (en)
Other versions
WO2000040273A8 (fr
WO2000040273A2 (fr
Inventor
Suezanne Parker
Holly Horton
Original Assignee
Vical Inc
Suezanne Parker
Holly Horton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vical Inc, Suezanne Parker, Holly Horton filed Critical Vical Inc
Publication of WO2000040273A2 publication Critical patent/WO2000040273A2/fr
Publication of WO2000040273A3 publication Critical patent/WO2000040273A3/fr
Publication of WO2000040273A8 publication Critical patent/WO2000040273A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé permettant de traiter une maladie virale, consistant à administrer à un mammifère une construction polynucléotidique qui comprend un polynucléotide codant pour IFNφ. La construction polynucléotidique de l'invention peut être administrée sans être associée à des agents facilitant la transfection ou sous forme d'un complexe renfermant au moins un ou plusieurs lipides cationiques.
PCT/US1999/030843 1999-01-08 1999-12-28 Traitement de maladies virales a l'aide d'un polynucleotide exprimant l'interferon omega WO2000040273A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11540399P 1999-01-08 1999-01-08
US60/115,403 1999-01-08

Publications (3)

Publication Number Publication Date
WO2000040273A2 WO2000040273A2 (fr) 2000-07-13
WO2000040273A3 true WO2000040273A3 (fr) 2000-11-16
WO2000040273A8 WO2000040273A8 (fr) 2001-01-11

Family

ID=22361168

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030843 WO2000040273A2 (fr) 1999-01-08 1999-12-28 Traitement de maladies virales a l'aide d'un polynucleotide exprimant l'interferon omega

Country Status (1)

Country Link
WO (1) WO2000040273A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875748B2 (en) 2000-04-21 2005-04-05 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
WO2002036072A2 (fr) 2000-11-03 2002-05-10 Biomedicines, Inc. Procede pour une dosimetrie de medicaments a court et a long terme
NZ532779A (en) * 2001-11-09 2008-04-30 Intarcia Therapeutics Inc Method for treating diseases with omega interferon
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2006083761A2 (fr) 2005-02-03 2006-08-10 Alza Corporation Solutions de solvant/polymere utilisees comme vehicules de suspension
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
EP2240155B1 (fr) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Dispositifs, formulations et méthodes d administration de plusieurs agents bénéfiques
CN107638562B (zh) 2009-09-28 2022-12-02 精达制药公司 基本稳态药物递送的快速建立和/或终止
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JP2013095755A (ja) * 2011-11-02 2013-05-20 Kyowa Hakko Kirin Co Ltd カチオン性脂質
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
BR112018073511A2 (pt) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
KR20230127977A (ko) * 2020-10-02 2023-09-01 이뮨온, 인코포레이티드 폴리뉴클레오티드 백신 및 이의 사용 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170204A2 (fr) * 1984-08-01 1986-02-05 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Séquences génétiques, interféron peptide du type I codé par celles-ci et les organismes les produisant
WO1996017063A1 (fr) * 1994-11-28 1996-06-06 Vical Incorporated Plasmides appropries a l'expression de l'il-2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170204A2 (fr) * 1984-08-01 1986-02-05 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Séquences génétiques, interféron peptide du type I codé par celles-ci et les organismes les produisant
WO1996017063A1 (fr) * 1994-11-28 1996-06-06 Vical Incorporated Plasmides appropries a l'expression de l'il-2

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 17 December 1998 (1998-12-17), AULT A: "FDA approves two new hepatitis therapies.", XP002144217, Database accession no. PREV199900076805 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1994, KOKOREVA L N ET AL: "Clinico-morphological characterization and effectiveness of interferon therapy in patients with chronic hepatitis delta.", XP002144216, Database accession no. PREV199497368940 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 1997 (1997-10-01), HUANG CHIU-CHING: "Hepatitis in patients with end-stage renal disease.", XP002144218, Database accession no. PREV199800049222 *
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 12, no. 9-10, October 1997 (1997-10-01), pages S236 - S241, ISSN: 0815-9319 *
LANCET (NORTH AMERICAN EDITION), vol. 352, no. 9145, 17 December 1998 (1998-12-17), pages 1996, ISSN: 0099-5355 *
RAZ EYAL ET AL: "Systemic immunological effects of cytokine genes injected into skeletal muscle.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 90, no. 10, 1993, 1993, pages 4523 - 4527, XP002144215, ISSN: 0027-8424 *
ZHURNAL MIKROBIOLOGII EPIDEMIOLOGII I IMMUNOBIOLOGII, no. 1, 1994, pages 55 - 59, ISSN: 0372-9311 *

Also Published As

Publication number Publication date
WO2000040273A8 (fr) 2001-01-11
WO2000040273A2 (fr) 2000-07-13

Similar Documents

Publication Publication Date Title
WO2000040273A8 (fr) Traitement de maladies virales a l'aide d'un polynucleotide exprimant l'interferon omega
WO2001081405A3 (fr) Methodes et compositions destinees a la prevention et au traitement de l'anemie
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
WO1996010419A3 (fr) Composition comprenant un virus de recombinaison exprimant un antigene et un virus de recombinaison exprimant une molecule immunostimulatrice
AU7295601A (en) Treatment of central nervous system diseases by antibodies against glatiramer acetate
HUP9800467A3 (en) Use of hyaluronic acid for producing pharmaceutical compns. for the treatment of interstitial cystitis
WO2002029087A3 (fr) Utilisation d'agents lymphangiogeniques pour le traitement de troubles lymphatiques
EP1758998A4 (fr) Oligoribonucleotides et procedes d'utilisation de ceux-ci dans le traitement d'etats fibreux et d'autres maladies
WO1999003508A3 (fr) TRAITEMENT DES MALADIES VASCULAIRES PROLIFERATIVES A L'AIDE DE p27 ET DE SES PROTEINES HYBRIDES
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
WO1999002143A3 (fr) Composition contenant un nucleotide
WO2001026639A3 (fr) Procede de traitement de troubles du metabolisme
EP0795332A3 (fr) Utilisation médicale de gamma interféron dans les maladies pulmonaires interstitielles
ZA200203269B (en) Nucleic acids of the human ABC1 gene and their therapeutic and diagnostic application.
IL142581A (en) Medicament for treating heart disease
DE60017174D1 (de) Rivastigmine zur behandlung von augenerkrankungen
WO1999021538A3 (fr) Utilisation de glycosaminoglycanes pour la fabrication de preparations pharmaceutiques en vue du traitement de maladies des yeux associees au diabete
WO2000043028A3 (fr) Therapie contre une affection cardiaque chronique
WO1994024279A3 (fr) Agents pour la prevention et le traitement de la choree de huntington et d'autres troubles neurologiques
WO2001014415A3 (fr) Gènes egfh2 et produits géniques
WO2001094570A3 (fr) Procede de transfection
WO2003059334A3 (fr) Gemcitabine pour traiter la variole
WO2001075021A3 (fr) Nouveau polypeptide, proteine humaine associee au transport de glucose 10, et polynucleotide codant pour ce polypeptide
李敏 CLINICAL OBSERVATION ON POSTHERPETIC NEURALGIA OF HIV CARRIERS TREATED WITH ARRANGED ELECTRO ACUPUNCTURE
WO2001068693A8 (fr) Nouveau polypeptide, proteine humaine de reception cannabinoide 7, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: C1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WR Later publication of a revised version of an international search report
122 Ep: pct application non-entry in european phase